Literature DB >> 15194002

[3H]OSIP339391, a selective, novel, and high affinity antagonist radioligand for adenosine A2B receptors.

Mike Stewart1, Arno G Steinig, Chienling Ma, Jian-Ping Song, Bryan McKibben, Arlindo L Castelhano, Stephen J MacLennan.   

Abstract

Until recently, the characterization of adenosine A(2B) receptors has been hampered by the lack of high affinity radioligands. This study describes the synthesis and in vitro characterization of the radiolabeled derivative of OSIP339391, a novel, potent, and selective pyrrolopyrimidine A(2B) antagonist. OSIP339391 had a selectivity of greater than 70-fold for A(2B) receptors over other human adenosine receptor subtypes. The radiolabel was introduced by hydrogenation of the acetylenic precursor with tritium gas resulting in the incorporation (on average) of three tritium atoms in the molecule, yielding a ligand with specific activity of 87Ci/mmol (3.2TBq/mmol). Using membranes from HEK-293 cells expressing the human recombinant A(2B) receptor, [3H]OSIP339391 was characterized in kinetic, saturation, and competition binding experiments. From the association and dissociation rate studies, the affinity was 0.41nM and in close agreement with that found in saturation binding experiments (0.17nM). In competition, binding studies using 0.5nM [3H]OSIP339391, the affinity of a range of agonists and antagonists was consistent with previously reported data. Thus, [3H]OSIP339391 is a novel, selective, and high affinity radioligand that can be a useful tool in the further exploration and characterization of recombinant and endogenous adenosine A(2B) receptors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15194002     DOI: 10.1016/j.bcp.2004.03.026

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  14 in total

Review 1.  Recent developments in adenosine receptor ligands and their potential as novel drugs.

Authors:  Christa E Müller; Kenneth A Jacobson
Journal:  Biochim Biophys Acta       Date:  2010-12-23

Review 2.  Adenosine receptors as therapeutic targets.

Authors:  Kenneth A Jacobson; Zhan-Guo Gao
Journal:  Nat Rev Drug Discov       Date:  2006-03       Impact factor: 84.694

3.  Homology modelling of the human adenosine A2B receptor based on X-ray structures of bovine rhodopsin, the beta2-adrenergic receptor and the human adenosine A2A receptor.

Authors:  Farag F Sherbiny; Anke C Schiedel; Astrid Maass; Christa E Müller
Journal:  J Comput Aided Mol Des       Date:  2009-11       Impact factor: 3.686

4.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

5.  Tritium-labeled agonists as tools for studying adenosine A2B receptors.

Authors:  Sonja Hinz; Wessam M Alnouri; Ulrich Pleiss; Christa E Müller
Journal:  Purinergic Signal       Date:  2018-05-11       Impact factor: 3.765

6.  Recent improvements in the development of A(2B) adenosine receptor agonists.

Authors:  Pier Giovanni Baraldi; Mojgan Aghazadeh Tabrizi; Francesca Fruttarolo; Romeo Romagnoli; Delia Preti
Journal:  Purinergic Signal       Date:  2009-01-31       Impact factor: 3.765

7.  Characterization of adenosine receptor in its native environment: insights from molecular dynamics simulations of palmitoylated/glycosylated, membrane-integrated human A(2B) adenosine receptor.

Authors:  Mahboubeh Mansourian; Armin Madadkar-Sobhani; Karim Mahnam; Afshin Fassihi; Lotfollah Saghaie
Journal:  J Mol Model       Date:  2012-05-09       Impact factor: 1.810

Review 8.  Progress in the pursuit of therapeutic adenosine receptor antagonists.

Authors:  Stefano Moro; Zhan-Guo Gao; Kenneth A Jacobson; Giampiero Spalluto
Journal:  Med Res Rev       Date:  2006-03       Impact factor: 12.388

9.  Characterization of human and rodent native and recombinant adenosine A(2B) receptors by radioligand binding studies.

Authors:  Daniela C G Bertarelli; Martina Diekmann; Alaa M Hayallah; Dorothee Rüsing; Jamshed Iqbal; Birgit Preiss; Eugen J Verspohl; Christa E Müller
Journal:  Purinergic Signal       Date:  2006-07-08       Impact factor: 3.765

10.  Progress in the discovery of selective, high affinity A(2B) adenosine receptor antagonists as clinical candidates.

Authors:  Rao V Kalla; Jeff Zablocki
Journal:  Purinergic Signal       Date:  2008-06-21       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.